JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eshleman, A. J.
Right arrow Articles by Janowsky, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eshleman, A. J.
Right arrow Articles by Janowsky, A.

Vol. 289, Issue 2, 877-885, May 1999

Characteristics of Drug Interactions with Recombinant Biogenic Amine Transporters Expressed in the Same Cell Type1

Amy J. Eshleman, Marya Carmolli, Medhane Cumbay, Carey R. Martens, Kim A. Neve and Aaron Janowsky

Research Service, Veterans Affairs Medical Center, and Departments of Physiology and Pharmacology (A.J.E., K.A.N., A.J.), Psychiatry (M. Carmolli, M. Cumbay, C.R.M., K.A.N., A.J.), and Behavioral Neuroscience (K.A.N., A.J.), Oregon Health Sciences University, Portland, Oregon

We characterized the effects of drugs on the uptake of [3H]neurotransmitter by and the binding of [125I](3beta -(4-iodophenyl)tropane-2beta -carboxylic acid methyl ester ([125I]RTI-55) to the recombinant human dopamine (hDAT), serotonin (hSERT), or norepinephrine (hNET) transporters stably expressed in human embryonic kidney 293 cells. RTI-55 had similar affinity for the hDAT and hSERT and lower affinity for hNET (Kd = 1.83, 0.98, and 12.1 nM, respectively). Kinetic analysis of [125I]RTI-55 binding indicated that the dissociation rate (k-1) was significantly lower for hSERT and the association rate (k+1) was significantly lower for hNET compared with the hDAT. The potency of drugs at blocking [3H]neurotransmitter uptake was highly correlated with potency at blocking radioligand binding for hDAT and hSERT. Substrates were more potent at the inhibition of [3H]neurotransmitter uptake than radioligand binding. The potency of drugs was highly correlated between displacement of [3H]nisoxetine (Kd = 6.0 nM) and [125I]RTI-55 from the hNET, suggesting that these radioligands recognize similar sites on the transporter protein. The correlation observed between inhibitory potency for uptake and binding of either ligand at the hNET was lower than correlations between uptake and binding for hDAT and hSERT. The present results indicate that the cocaine analog [125I]RTI-55 has unique binding properties at each of the transporters and that the use of recombinant transporters expressed by a single cell type can provide a powerful screening tool for drugs interacting with biogenic amine transporters, such as possible cocaine antagonists.

0022-3565/99/2892-0877$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
J. Andersen, O. Taboureau, K. B. Hansen, L. Olsen, J. Egebjerg, K. Stromgaard, and A. S. Kristensen
Location of the Antidepressant Binding Site in the Serotonin Transporter: IMPORTANCE OF SER-438 IN RECOGNITION OF CITALOPRAM AND TRICYCLIC ANTIDEPRESSANTS
J. Biol. Chem., April 10, 2009; 284(15): 10276 - 10284.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. X. Kelly, M. J. Smilkstein, R. A. Cooper, K. D. Lane, R. A. Johnson, A. Janowsky, R. A. Dodean, D. J. Hinrichs, R. Winter, and M. Riscoe
Design, Synthesis, and Evaluation of 10-N-Substituted Acridones as Novel Chemosensitizers in Plasmodium falciparum
Antimicrob. Agents Chemother., November 1, 2007; 51(11): 4133 - 4140.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
Z. Zhou, J. Zhen, N. K. Karpowich, R. M. Goetz, C. J. Law, M. E. A. Reith, and D.-N. Wang
LeuT-Desipramine Structure Reveals How Antidepressants Block Neurotransmitter Reuptake
Science, September 7, 2007; 317(5843): 1390 - 1393.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. S. Basile, A. Janowsky, K. Golembiowska, M. Kowalska, E. Tam, M. Benveniste, P. Popik, A. Nikiforuk, M. Krawczyk, G. Nowak, et al.
Characterization of the Antinociceptive Actions of Bicifadine in Models of Acute, Persistent, and Chronic Pain
J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1208 - 1225.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
A. Fowler, N. Seifert, V. Acker, T. Woehrle, C. Kilpert, and A. de Saizieu
A Nonradioactive High-Throughput/High-Content Assay for Measurement of the Human Serotonin Reuptake Transporter Function In Vitro
J Biomol Screen, December 1, 2006; 11(8): 1027 - 1034.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. M. Miller, C. D. Verrico, A. Jassen, M. Konar, H. Yang, H. Panas, M. Bahn, R. Johnson, and B. K. Madras
Primate Trace Amine Receptor 1 Modulation by the Dopamine Transporter
J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 983 - 994.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
M. J. Kreek, G. Bart, C. Lilly, K. S. Laforge, and D. A. Nielsen
Pharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments
Pharmacol. Rev., March 1, 2005; 57(1): 1 - 26.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
B. Beer, J. Stark, P. Krieter, P. Czobor, G. Beer, A. Lippa, and P. Skolnick
DOV 216,303, a "Triple" Reuptake Inhibitor: Safety, Tolerability, and Pharmacokinetic Profile
J. Clin. Pharmacol., December 1, 2004; 44(12): 1360 - 1367.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. J. Wilhelm, R. A. Johnson, P. G. Lysko, A. J. Eshleman, and A. Janowsky
Effects of Methamphetamine and Lobeline on Vesicular Monoamine and Dopamine Transporter-Mediated Dopamine Release in a Cotransfected Model System
J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1142 - 1151.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. K. Miller, P. A. Crooks, G. Zheng, V. P. Grinevich, S. D. Norrholm, and L. P. Dwoskin
Lobeline Analogs with Enhanced Affinity and Selectivity for Plasmalemma and Vesicular Monoamine Transporters
J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1035 - 1045.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Chen, J. Rickey, J. L. Berfield, and M. E. A. Reith
Aspartate 345 of the Dopamine Transporter Is Critical for Conformational Changes in Substrate Translocation and Cocaine Binding
J. Biol. Chem., February 13, 2004; 279(7): 5508 - 5519.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. L. Roman, S. N. Saldana, D. E. Nichols, F. I. Carroll, and E. L. Barker
Distinct Molecular Recognition of Psychostimulants by Human and Drosophila Serotonin Transporters
J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 679 - 687.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. A. Sharpe, E. Palant, C. I. Schroeder, D. M. Kaye, D. J. Adams, P. F. Alewood, and R. J. Lewis
Inhibition of the Norepinephrine Transporter by the Venom Peptide {chi}-MrIA: SITE OF ACTION, Na+ DEPENDENCE, AND STRUCTURE-ACTIVITY RELATIONSHIP
J. Biol. Chem., October 10, 2003; 278(41): 40317 - 40323.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
W. Wang, M. S. Sonders, O. T. Ukairo, H. Scott, M. K. Kloetzel, and C. K. Surratt
Dissociation of High-Affinity Cocaine Analog Binding and Dopamine Uptake Inhibition at the Dopamine Transporter
Mol. Pharmacol., August 1, 2003; 64(2): 430 - 439.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
F. Martel, R. Monteiro, and C. Lemos
Uptake of Serotonin at the Apical and Basolateral Membranes of Human Intestinal Epithelial (Caco-2) Cells Occurs through the Neuronal Serotonin Transporter (SERT)
J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 355 - 362.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
M. K. Hahn, D. Robertson, and R. D. Blakely
A Mutation in the Human Norepinephrine Transporter Gene (SLC6A2) Associated with Orthostatic Intolerance Disrupts Surface Expression of Mutant and Wild-Type Transporters
J. Neurosci., June 1, 2003; 23(11): 4470 - 4478.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J. A. Moron, A. Brockington, R. A. Wise, B. A. Rocha, and B. T. Hope
Dopamine Uptake through the Norepinephrine Transporter in Brain Regions with Low Levels of the Dopamine Transporter: Evidence from Knock-Out Mouse Lines
J. Neurosci., January 15, 2002; 22(2): 389 - 395.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
C. Roubert, C. Sagne, M. Kapsimali, P. Vernier, F. Bourrat, and B. Giros
A Na+/Cl--Dependent Transporter for Catecholamines, Identified as a Norepinephrine Transporter, Is Expressed in the Brain of the Teleost Fish Medaka (Oryzias latipes)
Mol. Pharmacol., September 1, 2001; 60(3): 462 - 473.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. J. Eshleman, K. Wolfrum, D. C. Mash, K. Christensen, and A. Janowsky
Drug Interactions with the Dopamine Transporter in Cryopreserved Human Caudate
J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 442 - 449.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
S. G. F. Rasmussen, F. I. Carroll, M. J. Maresch, A. D. Jensen, C. G. Tate, and U. Gether
Biophysical Characterization of the Cocaine Binding Pocket in the Serotonin Transporter Using a Fluorescent Cocaine Analogue as a Molecular Reporter
J. Biol. Chem., February 9, 2001; 276(7): 4717 - 4723.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.